𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis

✍ Scribed by P.C.M. Van De Kerkhof; J. Berth-Jones; C.E.M. Griffiths; P.V. Harrison; H. Hönigsmann; R. Marks; R. Roelandts; E. Schöpf; C. Trompke


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
122 KB
Volume
146
Category
Article
ISSN
0007-0963

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Repeat courses of intravenous alefacept
✍ Nick J. Lowe; John Gonzalez; Jerry Bagel; Ivor Caro; Charles N. Ellis; Alan Ment 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

## Abstract **Background** Psoriasis is a chronic, relapsing skin disease that may require multiple treatment courses. Alefacept targets the memory T cells implicated in psoriasis pathogenesis. This open‐label study evaluated the safety and tolerability, efficacy, and pharmacodynamics of repeat cou

Long-term outcome of severe chronic plaq
✍ Bleiker; Bourke; Mumford; Hutchinson 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

We have previously reported the effectiveness of high-dose calcipotriol in extensive psoriasis. We now report the long-term outcome in patients following this treatment. Twenty-eight patients with severe psoriasis were treated as in-patients with high-dose topical calcipotriol for 2 weeks. There was

A comparison of psoralen plus ultraviole
✍ S. Tzaneva; A. Seeber; H. Hönigsmann; A. Tanew 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

## Background: Numerous studies have shown that the additional administration of topical or systemic antipsoriatic agents might serve as an effective means to increase the efficacy of photochemotherapy [psoralen plus ultraviolet (uv) a (puva)] for psoriasis. ## Objectives: To compare the therapeu

Long-term safety and efficacy of long-ac
✍ Werner Kissling; Per Glue; Rossella Medori; Steve Simpson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 1 views

## Abstract This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot a